AB005. Development of tumour specific therapy for treatment of diffuse intrinsic pontine glioma (DIPG)
The present work details an effort to develop BBB crossing tumour specific therapeutic agents for the treatment of DIPG. The work has resulted in several promising drug-dye conjugates showing antiproliferative activity in various patient-derived DIPG cell lines, enabling the progression of such conjugates into animal models of DIPG. Such studies will inform the utility of such drug-dye conjugates for application in difficult to treat pHGGs such as DIPG.
Authors
- Maria Tsoli (ORCID: https://orcid.org/0000-0003-1155-0510)
- William A. Denny (ORCID: https://orcid.org/0000-0001-7997-1843)
- David S. Ziegler (ORCID: https://orcid.org/0000-0001-7451-7916)
- Jiney Jose (ORCID: https://orcid.org/0000-0002-1325-438X)
- Anjana Gopalakrishnan (ORCID: https://orcid.org/0009-0004-2146-0433)
- Peter Choi
- Carina Lee
- Thomas I I Park
Institutions
- University of Auckland (NZ)
- Cancer Society of New Zealand (NZ)
Publication Details
- Journal
- Chinese Clinical Oncology
- Published
- 2024-08-01
- DOI
- https://doi.org/10.21037/cco-24-ab005
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00